1. Home
  2. PLBL vs ARQT Comparison

PLBL vs ARQT Comparison

Compare PLBL & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBL

Polibeli Group Ltd Class A Ordinary Shares

N/A

Current Price

$8.80

Market Cap

3.0B

Sector

N/A

ML Signal

N/A

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$23.70

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBL
ARQT
Founded
2021
2016
Country
Indonesia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PLBL
ARQT
Price
$8.80
$23.70
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$34.00
AVG Volume (30 Days)
3.1K
1.1M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
88.79
EPS
N/A
N/A
Revenue
N/A
$376,072,000.00
Revenue This Year
N/A
$34.46
Revenue Next Year
N/A
$29.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
91.34
52 Week Low
$5.60
$11.86
52 Week High
$13.48
$31.77

Technical Indicators

Market Signals
Indicator
PLBL
ARQT
Relative Strength Index (RSI) 50.24 50.47
Support Level $7.38 $22.56
Resistance Level $9.68 $27.26
Average True Range (ATR) 0.59 0.95
MACD 0.07 0.28
Stochastic Oscillator 56.07 74.71

Price Performance

Historical Comparison
PLBL
ARQT

About PLBL Polibeli Group Ltd Class A Ordinary Shares

Polibeli Group Ltd is engaged in goods trading and others to promote the circulation of goods with a focus on making trading easier. The products offered by the company include consumer electronic accessories, household appliances, skincare products, oral-care products, cosmetics products, toys and game products, and health-care products. Geographically, the company derives the majority of its revenue from Japan.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: